Data Insights

CGX-1321 by Curegenix for Colorectal Cancer: Likelihood of Approval

CGX-1321 is under clinical development by Curegenix and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - CGX-1321 in Colorectal Cancer

Data Insights

CGX-1321 by Curegenix for Pancreatic Cancer: Likelihood of Approval

CGX-1321 is under clinical development by Curegenix and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - CGX-1321 in Pancreatic Cancer

Data Insights

CGX-1321 by Curegenix for Gastric Cancer: Likelihood of Approval

CGX-1321 is under clinical development by Curegenix and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - CGX-1321 in Gastric Cancer

Data Insights

CGX-1321 by Curegenix for Hepatocellular Carcinoma: Likelihood of Approval

CGX-1321 is under clinical development by Curegenix and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - CGX-1321 in Hepatocellular Carcinoma

Data Insights

CGX-1321 by Curegenix for Esophageal Cancer: Likelihood of Approval

CGX-1321 is under clinical development by Curegenix and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - CGX-1321 in Esophageal Cancer

Data Insights

CGX-1321 by Curegenix for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

CGX-1321 is under clinical development by Curegenix and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - CGX-1321 in Bile Duct Cancer (Cholangiocarcinoma)